Mishal Pandie1, Lubbe Wiesner1, Helen McIlleron1, Jennifer Hughes2, Sweetness Siwendu3, Francesca Conradie4, Ebrahim Variava5, Gary Maartens6. 1. Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa. 2. Brooklyn Chest Hospital, Cape Town, South Africa. 3. Médecins sans Frontières, Khayelitsha, Cape Town, South Africa. 4. Department of Internal Medicine, University of the Witwatersrand, Johannesburg, South Africa Right to Care, Johannesburg, South Africa. 5. Department of Internal Medicine, University of the Witwatersrand, Johannesburg, South Africa. 6. Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa gary.maartens@uct.ac.za.
Abstract
OBJECTIVES: Bedaquiline is a new anti-TB drug, which is metabolized by cytochrome P450 (CYP) 3A4. Concomitant ART is important for all HIV-infected patients treated for TB, but several antiretrovirals inhibit or induce CYP3A4. Single-dose drug-drug interaction studies found no significant interactions with nevirapine or lopinavir/ritonavir, but these findings could be misleading, especially because of bedaquiline's long terminal t1/2. We evaluated the effect of nevirapine and lopinavir/ritonavir on bedaquiline exposure. METHODS: We conducted a parallel-group pharmacokinetic study of three groups of participants who were on bedaquiline as part of therapy for drug-resistant TB: no ART (HIV seronegative); nevirapine-based ART; and lopinavir/ritonavir-based ART. Non-compartmental analyses were done and exposure of bedaquiline and its M2 metabolite compared between the no-ART group and the two ART groups. RESULTS: We enrolled 48 participants: 17 in the no-ART group, 17 in the nevirapine group and 14 in the lopinavir/ritonavir group. The following median bedaquiline pharmacokinetic parameters were significantly higher in the lopinavir/ritonavir group than in the no-ART group: AUC(0-48) (67 002 versus 34 730 ng · h/mL; P = 0.003); Tmax (6 versus 4 h; P = 0.003); and t1/2 (55 versus 31 h; P = 0.004). On multivariate analysis, bedaquiline exposure was increased by lopinavir/ritonavir, male sex and time on bedaquiline. Bedaquiline exposure was not significantly different between the nevirapine group and the no-ART group. M2 metabolite exposure was not significantly different in either of the antiretroviral groups compared with the no-ART group. CONCLUSIONS: Lopinavir/ritonavir significantly increased bedaquiline exposure. The clinical significance of this interaction remains to be determined.
OBJECTIVES:Bedaquiline is a new anti-TB drug, which is metabolized by cytochrome P450 (CYP) 3A4. Concomitant ART is important for all HIV-infectedpatients treated for TB, but several antiretrovirals inhibit or induce CYP3A4. Single-dose drug-drug interaction studies found no significant interactions with nevirapine or lopinavir/ritonavir, but these findings could be misleading, especially because of bedaquiline's long terminal t1/2. We evaluated the effect of nevirapine and lopinavir/ritonavir on bedaquiline exposure. METHODS: We conducted a parallel-group pharmacokinetic study of three groups of participants who were on bedaquiline as part of therapy for drug-resistant TB: no ART (HIV seronegative); nevirapine-based ART; and lopinavir/ritonavir-based ART. Non-compartmental analyses were done and exposure of bedaquiline and its M2 metabolite compared between the no-ART group and the two ART groups. RESULTS: We enrolled 48 participants: 17 in the no-ART group, 17 in the nevirapine group and 14 in the lopinavir/ritonavir group. The following median bedaquiline pharmacokinetic parameters were significantly higher in the lopinavir/ritonavir group than in the no-ART group: AUC(0-48) (67 002 versus 34 730 ng · h/mL; P = 0.003); Tmax (6 versus 4 h; P = 0.003); and t1/2 (55 versus 31 h; P = 0.004). On multivariate analysis, bedaquiline exposure was increased by lopinavir/ritonavir, male sex and time on bedaquiline. Bedaquiline exposure was not significantly different between the nevirapine group and the no-ART group. M2 metabolite exposure was not significantly different in either of the antiretroviral groups compared with the no-ART group. CONCLUSIONS:Lopinavir/ritonavir significantly increased bedaquiline exposure. The clinical significance of this interaction remains to be determined.
Authors: David W Haas; Mahmoud Tareq Abdelwahab; Stijn W van Beek; Paxton Baker; Gary Maartens; Yuki Bradford; Marylyn D Ritchie; Sean Wasserman; Graeme Meintjes; Karen Beeri; Neel R Gandhi; Elin M Svensson; Paolo Denti; James C M Brust Journal: J Infect Dis Date: 2022-08-12 Impact factor: 7.759
Authors: Elin M Svensson; Jeannine du Bois; Rene Kitshoff; Veronique R de Jager; Lubbe Wiesner; Jennifer Norman; Sharon Nachman; Betsy Smith; Andreas H Diacon; Anneke C Hesseling; Anthony J Garcia-Prats Journal: Br J Clin Pharmacol Date: 2018-06-27 Impact factor: 4.335
Authors: Catherine Wei Min Ong; Giovanni Battista Migliori; Mario Raviglione; Gavin MacGregor-Skinner; Giovanni Sotgiu; Jan-Willem Alffenaar; Simon Tiberi; Cornelia Adlhoch; Tonino Alonzi; Sophia Archuleta; Sergio Brusin; Emmanuelle Cambau; Maria Rosaria Capobianchi; Concetta Castilletti; Rosella Centis; Daniela M Cirillo; Lia D'Ambrosio; Giovanni Delogu; Susanna M R Esposito; Jose Figueroa; Jon S Friedland; Benjamin Choon Heng Ho; Giuseppe Ippolito; Mateja Jankovic; Hannah Yejin Kim; Senia Rosales Klintz; Csaba Ködmön; Eleonora Lalle; Yee Sin Leo; Chi-Chiu Leung; Anne-Grete Märtson; Mario Giovanni Melazzini; Saeid Najafi Fard; Pasi Penttinen; Linda Petrone; Elisa Petruccioli; Emanuele Pontali; Laura Saderi; Miguel Santin; Antonio Spanevello; Reinout van Crevel; Marieke J van der Werf; Dina Visca; Miguel Viveiros; Jean-Pierre Zellweger; Alimuddin Zumla; Delia Goletti Journal: Eur Respir J Date: 2020-10-01 Impact factor: 16.671
Authors: Tom G Jacobs; Elin M Svensson; Victor Musiime; Pablo Rojo; Kelly E Dooley; Helen McIlleron; Rob E Aarnoutse; David M Burger; Anna Turkova; Angela Colbers Journal: J Antimicrob Chemother Date: 2020-12-01 Impact factor: 5.790